Literature DB >> 18076107

Confronting complexity in late-onset Alzheimer disease: application of two-stage analysis approach addressing heterogeneity and epistasis.

Tricia A Thornton-Wells1, Jason H Moore, Eden R Martin, Margaret A Pericak-Vance, Jonathan L Haines.   

Abstract

Common diseases with a genetic basis are likely to have a very complex etiology, in which the mapping between genotype and phenotype is far from straightforward. A new comprehensive statistical and computational strategy for identifying the missing link between genotype and phenotype has been proposed, which emphasizes the need to address heterogeneity in the first stage of any analysis and gene-gene interactions in the second stage. We applied this two-stage analysis strategy to late-onset Alzheimer disease (LOAD) data, which included functional and positional candidate genes and markers in a region of interest on chromosome 10. Bayesian classification found statistically significant clusterings for independent family-based and case-control datasets, which used the same five markers in leucine-rich repeat transmembrane neuronal 3 (LRRTM3) as the most influential in determining cluster assignment. In subsequent analyses to detect main effects and gene-gene interactions, markers in three genes--urokinase-type plasminogen activator (PLAU), angiotensin 1 converting enzyme (ACE) and cell division cycle 2 (CDC2)--were found to be associated with LOAD in particular subsets of the data based on their LRRTM3 multilocus genotype. All of these genes are viable candidates for LOAD based on their known biological function, even though PLAU, CDC2 and LRRTM3 were initially identified as positional candidates. Further studies are needed to replicate these statistical findings and to elucidate possible biological interaction mechanisms between LRRTM3 and these genes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18076107      PMCID: PMC2804868          DOI: 10.1002/gepi.20294

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  64 in total

1.  Correcting for a potential bias in the pedigree disequilibrium test.

Authors:  E R Martin; M P Bass; N L Kaplan
Journal:  Am J Hum Genet       Date:  2001-04       Impact factor: 11.025

2.  Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions.

Authors:  Lance W Hahn; Marylyn D Ritchie; Jason H Moore
Journal:  Bioinformatics       Date:  2003-02-12       Impact factor: 6.937

3.  Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity.

Authors:  Marylyn D Ritchie; Lance W Hahn; Jason H Moore
Journal:  Genet Epidemiol       Date:  2003-02       Impact factor: 2.135

4.  A novel gene family encoding leucine-rich repeat transmembrane proteins differentially expressed in the nervous system.

Authors:  Juha Laurén; Matti S Airaksinen; Mart Saarma; Tõnis Timmusk
Journal:  Genomics       Date:  2003-04       Impact factor: 5.736

5.  The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-epsilon4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Abeta(1-42) level.

Authors:  Marzia Pesaresi; Sara Batelli; Francesca Prato; Letizia Polito; Carlo Lovati; Elio Scarpini; Pierluigi Quadri; Claudio Mariani; Diego Albani; Gianluigi Forloni
Journal:  Neurobiol Dis       Date:  2006-12-15       Impact factor: 5.996

6.  A second locus for very-late-onset Alzheimer disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region.

Authors:  Jane M Olson; Katrina A B Goddard; Doreen M Dudek
Journal:  Am J Hum Genet       Date:  2002-05-15       Impact factor: 11.025

7.  Increased frequency of a new polymorphism in the cell division cycle 2 (cdc2) gene in patients with Alzheimer's disease and frontotemporal dementia.

Authors:  A Johansson; H Hampel; F Faltraco; K Buerger; L Minthon; N Bogdanovic; M Sjögren; H Zetterberg; L Forsell; L Lilius; L O Wahlund; L Rymo; J A Prince; K Blennow
Journal:  Neurosci Lett       Date:  2003-04-03       Impact factor: 3.046

8.  Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity.

Authors:  J Hu; A Igarashi; M Kamata; H Nakagawa
Journal:  J Biol Chem       Date:  2001-10-16       Impact factor: 5.157

9.  alphaT-catenin: a novel tissue-specific beta-catenin-binding protein mediating strong cell-cell adhesion.

Authors:  B Janssens; S Goossens; K Staes; B Gilbert; J van Hengel; C Colpaert; E Bruyneel; M Mareel; F van Roy
Journal:  J Cell Sci       Date:  2001-09       Impact factor: 5.285

Review 10.  A comprehensive review of genetic association studies.

Authors:  Joel N Hirschhorn; Kirk Lohmueller; Edward Byrne; Kurt Hirschhorn
Journal:  Genet Med       Date:  2002 Mar-Apr       Impact factor: 8.822

View more
  11 in total

1.  Angiotensin-converting enzyme gene polymorphisms and risk for sporadic Alzheimer's disease: a meta-analysis.

Authors:  Xue-Bin Wang; Ning-Hua Cui; Jia-Jia Gao; Xue-Ping Qiu; Na Yang; Fang Zheng
Journal:  J Neural Transm (Vienna)       Date:  2014-05-23       Impact factor: 3.575

2.  Phosphorylation of amyloid-β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes.

Authors:  Sathish Kumar; Sandesh Singh; Désirée Hinze; Michaele Josten; Hans-Georg Sahl; Martin Siepmann; Jochen Walter
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

3.  Whole genome association analysis shows that ACE is a risk factor for Alzheimer's disease and fails to replicate most candidates from Meta-analysis.

Authors:  Jennifer Webster; Eric M Reiman; Victoria L Zismann; Keta D Joshipura; John V Pearson; Diane Hu-Lince; Matthew J Huentelman; David W Craig; Keith D Coon; Thomas Beach; Kristen C Rohrer; Alice S Zhao; Doris Leung; Leslie Bryden; Lauren Marlowe; Mona Kaleem; Diego Mastroeni; Andrew Grover; Joseph Rogers; Reinhard Heun; Frank Jessen; Heike Kölsch; Christopher B Heward; Rivka Ravid; Michael L Hutton; Stacey Melquist; Ron C Petersen; Richard J Caselli; Andreas Papassotiropoulos; Dietrich A Stephan; John Hardy; Amanda Myers
Journal:  Int J Mol Epidemiol Genet       Date:  2009-07-26

4.  Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes.

Authors:  Scott Miners; Emma Ashby; Shabnam Baig; Rachel Harrison; Hannah Tayler; Elizabeth Speedy; Jonathan A Prince; Seth Love; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2009-01-18       Impact factor: 4.060

Review 5.  The Role of the Renin-Angiotensin System in Amyloid Metabolism of Alzheimer's Disease.

Authors:  Chao-Liang Chou; Hung-I Yeh
Journal:  Acta Cardiol Sin       Date:  2014-03       Impact factor: 2.672

Review 6.  Control of neural circuit formation by leucine-rich repeat proteins.

Authors:  Joris de Wit; Anirvan Ghosh
Journal:  Trends Neurosci       Date:  2014-08-14       Impact factor: 13.837

7.  Genetic association of urokinase-type plasminogen activator gene rs2227564 site polymorphism with sporadic Alzheimer's disease in the Han Chinese population.

Authors:  Xuelian Ji; Longfei Jia; Jianping Jia; Li Qi
Journal:  Neural Regen Res       Date:  2012-10-25       Impact factor: 5.135

8.  LRRTM3 interacts with APP and BACE1 and has variants associating with late-onset Alzheimer's disease (LOAD).

Authors:  Sarah Lincoln; Mariet Allen; Claire L Cox; Louise P Walker; Kimberly Malphrus; Yushi Qiu; Thuy Nguyen; Christopher Rowley; Naomi Kouri; Julia Crook; V Shane Pankratz; Samuel Younkin; Linda Younkin; Minerva Carrasquillo; Fanggeng Zou; Samer O Abdul-Hay; Wolfdieter Springer; Sigrid B Sando; Jan O Aasly; Maria Barcikowska; Zbigniew K Wszolek; Jada M Lewis; Dennis Dickson; Neill R Graff-Radford; Ronald C Petersen; Elizabeth Eckman; Steven G Younkin; Nilüfer Ertekin-Taner
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

9.  Role of genetic heterogeneity and epistasis in bladder cancer susceptibility and outcome: a learning classifier system approach.

Authors:  Ryan John Urbanowicz; Angeline S Andrew; Margaret Rita Karagas; Jason H Moore
Journal:  J Am Med Inform Assoc       Date:  2013-02-26       Impact factor: 4.497

Review 10.  Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.

Authors:  J Scott Miners; Jennifer C Palmer; Hannah Tayler; Laura E Palmer; Emma Ashby; Patrick G Kehoe; Seth Love
Journal:  Front Aging Neurosci       Date:  2014-09-11       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.